Physician profile
Nathan C Darby
NPI 1649470147
$762.41
in general payments reported to CMS, 2019-2025
12 companies · $211 in 2025
The $211 reported for 2025 was more than what a typical Sports Medicine (Family Medicine) provider received nationally (typical 2025 total: $113).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $255 · 2020: $73.00 · 2021: $69.13 · 2023: $47.85 · 2024: $106 · 2025: $211.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $365.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $364.82 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ferring Pharmaceuticals INC. | $252.62 | 2019-2025 | Euflexxa |
| Pacira Therapeutics, INC. | $101.50 | 2019-2021 | |
| Bioventus LLC | $67.57 | 2025 | Durolane, Xcell |
| Depuy Synthes Sales INC. | $63.96 | 2020-2024 | Monovisc, Orthovisc |
| Fidia Pharma USA INC. | $59.61 | 2019-2021 | |
| Horizon Therapeutics Plc | $50.50 | 2019-2020 | |
| Kerecis Limited | $46.12 | 2025 | Kerecis Surgiclose, Kerecis Graftguide |
| Organogenesis INC. | $33.61 | 2024 | Puraply Am |
| Zimmer Biomet Holdings, INC. | $32.55 | 2024 | Gps III Platelet Concentration System |
| Pacira Pharmaceuticals Incorporated | $26.81 | 2023 | Exparel, Zilretta, Iovera |
| Orthogenrx INC. | $17.39 | 2019 | |
| Orthofix Medical, INC. | $10.17 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nathan Darby listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.